Skip to main content
Premium Trial:

Request an Annual Quote

Short Reads: Sep 1, 2002 (rev. 1)

Premium

This month, Applera and Caltech will deliver their response to the MJ Research lawsuit aimed at invalidating the four-color automated DNA sequencing patents held by Caltech and licensed to Applied Biosystems. The response, which must address each complaint filed by MJ, is due on September 23.

 

JGI announced that the international team it led has completed the draft Fugu rubripes pufferfish sequence, assembly, and analysis. Meantime, the mouse consortium mapped the mouse genome and came up with 296 contigs and 16,992 unique markers.

 

NIH awarded $15.5 million to the Molecular Sciences Institute, led by Roger Brent, to support its Center for Genomic Experimentation and Computation. The center was among the four chosen by the government as Centers of Excellence in Genomic Science.

 

New digs: Accelrys opened new UK headquarters at a 42,000-square-foot facility in Cambridge. Indiana University and its Advanced Research and Technology Institute bought a 55,000-square-foot building for their new life science incubator, expected to spin out IP from the Indiana Genomics Initiative, the Indiana Proteomics Consortium, and the School of Informatics, among others.

 

Amersham Biosciences and the Sloan-Kettering Institute teamed up for a two-year project in functional proteomics with the goal of developing new technology to scan the human genome in a day to test each gene for function.

 

The UK’s Department of Trade and Industry, Genetix, and the Medical Research Council are jointly funding a £2.5 million proteomics collaboration between Genetix, a robotics firm, and the Human Genome Mapping Project Resource Centre in Cambridge, UK.

 

Vacaville, Calif.-based Large Scale Biology won a $12.3 million, five-year contract with the National Institute of Environmental Health Sciences for the National Center for Toxicogenomics. LSBC’s Maryland-based proteomics division will handle most of the work, which entails using proteomics to analyze samples each year.

 

The SNP Consortium announced the completion of a genome-wide linkage map based on human SNPs. The map is available for free online.

 

Oxford GlycoSciences and the Cystic Fibrosis Foundation launched a proteomics-based research collaboration to find markers of cystic fibrosis and linked complications.

 

Affymetrix received a $4 million NIH grant for continued mapping of hidden transcriptional activity. Affy has been working on this project in conjunction with NCI.

 

Zyomyx must know where the money is. The company announced a $27 million round of late-stage funding led by Credit Suisse First Boston Private Equity.

 

DOE’s Genomes to Life program announced funding of $103 million over the next five years for post-genomic research. Among the recipients: Argonne, Lawrence Berkeley, Los Alamos, Oak Ridge, Pacific Northwest, and Sandia National Labs; Brigham and Women’s Hospital; Diversa; Harvard Medical School; Massachusetts General Hospital; MIT; National Center for Genome Resources; The Institute for Genomic Research; The Molecular Sciences Institute; University of California; University of Illinois; University of Massachusetts; University of Michigan; University of Missouri; University of North Carolina; University of Tennessee; University of Utah; and University of Washington.

 

Linux Networx is designing a supercomputer for Lawrence Livermore National Laboratory, due to be delivered by this fall. The 1,920-processor cluster, expected to be one of the five fastest in the world, will be used extensively for bioinformatics research.

 

The Pennsylvania Cancer Alliance has been awarded $5.5 million of tobacco settlement money by the state’s health department to create a bioinformatics consortium for cancer research. The consortium will be led by the University of Pittsburgh Cancer Institute.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.